Moderna, Inc.

Moderna, Inc. operates as a pioneering biotechnology firm, leveraging its proprietary messenger RNA (mRNA) technology platform to develop and commercialize a diverse portfolio of medicines. The company's integrated business model spans discovery, development, manufacturing, and commercialization, underpinned by a belief in the platform's advantages, including accelerated development, reduced portfolio risk, and capital efficiency through shared manufacturing processes. Currently, Moderna commercializes three key products: Spikevax and mNEXSPIKE, both COVID-19 vaccines, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Notably, mNEXSPIKE, launched commercially in the third quarter of 2025, has rapidly ascended to become the leading product in the U.S. retail channel, demonstrating strong market acceptance. The company has also significantly expanded its global manufacturing footprint, with new drug product capabilities in the U.S. and three Moderna-built and managed facilities in the UK, Canada, and Australia, all fully licensed in 2025 and supported by multi-year government purchase commitments.

The competitive landscape for Moderna is characterized by intense rivalry within the rapidly advancing biotechnology and pharmaceutical industries. In the seasonal vaccine market, the company faces formidable competition from established players like Pfizer and BioNTech, which also utilize mRNA technology for COVID vaccines, as well as from Sanofi and Novavax. The market is further complicated by fragmented customer bases, unpredictable order patterns, and aggressive market practices involving rebates and discounts. For its RSV vaccine, mRESVIA, Moderna entered a market already occupied by Pfizer and GlaxoSmithKline, which has resulted in minimal sales to date and challenges in securing significant market share. Beyond vaccines, the oncology space presents a highly dynamic and competitive environment, with numerous companies developing a broad range of products and platforms, where new standards of care can emerge rapidly, potentially impacting Moderna's commercial opportunities and development timelines.

Financially, Moderna reported total revenue of $1.9 billion for fiscal year 2025, marking a substantial 40% decrease from $3.2 billion in 2024, primarily driven by reduced demand for its COVID-19 vaccines and the completion of advance purchase agreements with government customers. Net product sales, the predominant revenue component, similarly fell by 42% to $1.8 billion. Despite the significant revenue decline, the company demonstrated improved cost management, narrowing its net loss per share to $(7.26) in 2025 from $(9.28) in 2024. Operating expenses saw substantial reductions across the board, with cost of sales decreasing by 41% to $868 million, research and development (R&D) expenses falling by 31% to $3.1 billion due to portfolio prioritization and the wind-down of large Phase 3 respiratory programs, and selling, general and administrative (SG&A) expenses declining by 13% to $1.0 billion. As of December 31, 2025, the company maintained a robust liquidity position with $8.1 billion in cash, cash equivalents, and investments, supplemented by a new $1.5 billion five-year term loan facility, of which $600 million was drawn by year-end.

Moderna is strategically focused on four key priorities to drive future growth and achieve long-term profitability. First, the company aims to deliver sales growth through geographic expansion and new product launches, anticipating a return to revenue growth in 2026, primarily from the annualized impact of its international partnerships and the continued strong uptake of mNEXSPIKE in the U.S., with further growth opportunities projected for 2027 and 2028. Second, a strong emphasis is placed on delivering cost efficiency across the business, building on disciplined cost management in 2025 and projecting further reductions in 2026 and 2027 by leveraging its global production network, artificial intelligence, and digital tools to achieve targeted cash breakeven. Third, Moderna is committed to executing on its prioritized pipeline, expecting pivotal trial data readouts in 2026 across its oncology, rare disease, and infectious disease portfolios, and anticipating the launch of several new infectious disease products in the coming years, with cash generated from these products intended for investment into oncology and rare disease therapeutics. Finally, the company continues to advance its early pipeline and platform technology, including early-stage oncology and vaccine programs.

The company's extensive pipeline includes 35 therapeutic and vaccine programs, with six in late-stage development, underscoring its commitment to innovation. In oncology, the individualized neoantigen therapy intismeran autogene (mRNA-4157), developed in collaboration with Merck, has shown sustained improvement in recurrence-free survival in high-risk melanoma patients over five years and is currently in eight Phase 2 and Phase 3 clinical trials. Regulatory filings are also under review for the seasonal flu+COVID combination vaccine candidate (mRNA-1083) in Europe and Canada, and for the seasonal flu vaccine candidate (mRNA-1010) in the United States, Europe, Canada, and Australia, with a PDUFA goal date of August 5, 2026, for mRNA-1010. In rare diseases, the propionic acidemia therapeutic (mRNA-3927) has reached target enrollment in a registrational study, and a strategic partnership with Recordati has been established for its global commercialization. These pipeline advancements, coupled with the ongoing expansion of its global manufacturing network, including the onshoring of drug product manufacturing to its Norwood, Massachusetts facility by the first half of 2027, are central to the company's long-term growth strategy.

Despite these ambitious growth plans, Moderna anticipates continued negative cash flows from operations in upcoming periods due to significant ongoing investments in future product launches and pipeline advancement. The success of its cost reduction measures in aligning with expectations is not guaranteed, and the timing of near-term product launches remains uncertain. Furthermore, the company operates in a highly competitive environment, particularly in the seasonal vaccine market and the rapidly evolving oncology space, which could pose structural headwinds to market share gains and profitability. The inherent length, uncertainty, and cost of clinical development, coupled with complex regulatory hurdles and the need for broad market acceptance and favorable reimbursement policies, represent execution risks to the company's growth plan.

Moderna faces a broad spectrum of material risks encompassing macroeconomic, regulatory, geopolitical, and operational factors. Macroeconomic risks include general economic conditions, war, political instability, tariffs, and fluctuations in interest rates and inflation. Regulatory uncertainties are significant, stemming from evolving public health recommendations, changes in reimbursement policies such as the Inflation Reduction Act and potential "most-favored-nation" pricing models, drug reimportation policies, and complex global regulatory approval processes, alongside stringent data privacy laws like GDPR and CCPA, and anti-bribery statutes. Geopolitical risks are amplified by expanding international operations, exposing the company to diverse regulatory, tax, legal, cultural, and economic challenges. Operationally, the company confronts demand forecasting difficulties leading to inventory write-downs, intense competition, the lengthy and uncertain nature of clinical development with inherent risks of trial failures or adverse events, and complex manufacturing challenges related to scale-up, quality control, cGMP compliance, cold-chain logistics, and dependence on single-source suppliers. The unique, patient-specific manufacturing process for intismeran autogene introduces additional complexities, while cybersecurity threats, including those leveraging AI, pose significant risks to digital infrastructure and data integrity. Furthermore, the company is embroiled in extensive intellectual property litigation with numerous parties, including Pfizer/BioNTech, Arbutus/Genevant, and GlaxoSmithKline, which could result in substantial costs, weakened IP rights, or commercialization blocks. Financial risks include the expectation of continued net losses and negative cash flows, stock price volatility, and potential securities class-action litigation.

Management's forward-looking statements convey a clear strategic vision centered on advancing a new class of mRNA medicines through continuous scientific, delivery, and manufacturing advancements. The overall tone is one of confidence in the mRNA platform's potential and a commitment to long-term growth, despite acknowledging near-term financial challenges. Management emphasizes the successful transition from a research-stage entity to a commercial enterprise with a diverse clinical portfolio and integrated manufacturing capabilities. A key strategic priority highlighted is the establishment of a robust and localized global manufacturing infrastructure, including new facilities in the UK, Australia, and Canada, and the onshoring of drug product manufacturing in the U.S., all designed to support local supply, enhance pandemic preparedness, and provide rapid response capabilities. Financially, management is focused on disciplined cost management and operational efficiency, reflected in the significant expense reductions in 2025 and projections for a "modest reduction" in R&D expenses in 2026, with SG&A expected to remain consistent, aiming for an "efficient and scalable operating structure" and cash breakeven. The securing of a $1.5 billion credit facility underscores a proactive approach to enhancing financial flexibility. Management projects product sales to "return to growth in 2026," driven by international partnerships and mNEXSPIKE uptake, while acknowledging the expectation of continued negative cash flows from operations due to significant investments in future product launches and pipeline advancement, signaling a sustained, long-term growth-oriented strategy.